Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | CPA1 | P15085 | 3/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168647 | 0.83 | ACE (0.60) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL10168296 | 0.81 | ACE (0.54) | MMEACECPA1ACE2CTSD | |
| SCHEMBL10168284 | 0.81 | ACE (0.54) | MMEACECPA1ACE2CTSD | |
| SCHEMBL10168637 | 0.81 | ACE (0.54) | MMEACECPA1ACE2CTSD | |
| SCHEMBL17991788 | 0.79 | CTSB (0.51) | F2RL1CTSDALDH1A1SMN1; SMN2 | |
| SCHEMBL25903271 | 0.77 | HSD17B10 (0.49) | ACEKMT2A | |
| SCHEMBL21261550 | 0.76 | ACE (0.61) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL10168828 | 0.75 | ACE (0.55) | MMEACECPA1ACE2MMP1 | |
| SCHEMBL15649661 | 0.75 | ACE (0.61) | MMEACECPA1ACE2KMT2A | |
| SCHEMBL27146722 | 0.75 | KMT2A (0.54) | ACE2KMT2AMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | CDK4 2418/4885CCNA2 4410/4885CCND1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.